Pyrotinib

$228$3,540

Products Details

Product Description

– Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively[1].

Web ID

– HY-104065

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Cancer-Kinase/protease

Molecular Formula

– C32H31ClN6O3

Citations

– Biosci Rep. 2020 Feb 28;40(2):BSR20194167.|Cell Rep Med. 2023 Jan 10;100911.|Int J Biol Macromol. 2023 May 19;242(Pt 2):124870.|J Med Chem. 2019 May 9;62(9):4772-4778.|J Thorac Oncol. 2023 Sep 5;S1556-0864(23)00802-X.|Lung Cancer. 2018 Dec;126:72-79.|Patent. US 20220175778A1.|Patent. US20210361655A1.|Open Life Sci. 2023, 18(1).

References

– [1]Li X, et al. Discovery and development of Pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017 Jan 21. pii: S0928-0987(17)30043-X.

CAS Number

– 1269662-73-8

Molecular Weight

– 583.08

Compound Purity

– 99.80

SMILES

– O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/[C@@H]5N(C)CCC5

Clinical Information

– Launched

Research Area

– Cancer

Solubility

– DMSO : 10 mg/mL (ultrasonic;adjust pH to 6 with HCl)

Target

– EGFR

Isoform

– EGFR/ErbB1/HER1;ErbB2/HER2

Pathway

– JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=